Apogee Therapeutics (NASDAQ: APGE) saw its stock plummet 5.18% in Monday's pre-market trading, despite announcing positive 16-week data from its Phase 2 APEX clinical trial of APG777, a potential best-in-class anti-IL-13 antibody for moderate-to-severe atopic dermatitis.
The company reported that Part A of the trial met all primary and key secondary endpoints, with APG777 showing a 71.0% decrease from baseline in the Eczema Area and Severity Index (EASI) at Week 16, compared to 33.8% for placebo. Additionally, 66.9% of participants treated with APG777 achieved EASI-75, the highest response rate for any biologic in a global study to date.
Despite these encouraging results, the stock's unexpected decline suggests investors may be reacting to other factors. Possible explanations include profit-taking following the news, concerns about the drug's commercialization prospects, or broader market trends affecting biotech stocks. The contradiction between the positive trial results and the stock's performance highlights the complex nature of investor sentiment in the biotech sector.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。